公开(公告)号：US20230405138A1

公开(公告)日：2023-12-21

申请号：US18018241

申请日：2021-07-27

申请人： TUOJIE BIOTECH (SHANGHAI) CO., LTD.

发明人： Wenming REN ,  Jindong LIANG ,  Jianyan XU ,  Jian HUANG ,  Changyong YANG ,  Cheng LIAO

IPC分类号： A61K47/68 ,  C07K16/28 ,  A61P35/00

CPC分类号： A61K47/6849 ,  A61K47/68031 ,  C07K16/2803 ,  A61P35/00 ,  C07K2317/33 ,  C07K2317/24 ,  C07K2317/92

摘要： Provided are an anti-CD79B antibody-drug conjugate, and a preparation method therefor and pharmaceutical use thereof. In particular, provided are an antibody-drug conjugate (ADC) which comprises an anti-CD79B antibody conjugated with an MMAE or a derivative thereof, exatecan or a derivative thereof, or Eribulin or a derivative thereof, a pharmaceutical composition containing the ADC, and use thereof in preparation of a drug for treatment of a CD79B-mediated disease or disorder, especially use thereof in preparation of an anti-cancer drug.

公开(公告)号：US20230390411A1

公开(公告)日：2023-12-07

申请号：US18037884

申请日：2022-01-28

申请人： NANJING CHEMPION BIOTECHNOLOGY CO., LTD.

发明人： Jian Chen ,  Haibo Zhao ,  Rong Gu

IPC分类号： A61K47/68 ,  A61K47/60 ,  A61K31/35 ,  A61P35/00 ,  A61K31/4741

CPC分类号： A61K47/68031 ,  A61K47/60 ,  A61K31/35 ,  A61P35/00 ,  A61K31/4741

摘要： A compound of formula (I), or a tautomer, a stereoisomer or a pharmaceutically acceptable salt thereof. The compound represented by formula (I) or the tautomer, the stereoisomer or the pharmaceutically acceptable salt thereof, as a novel linker compound, can be used for preparing an ADC medicament with a high DAR value. The present invention also relates to an ADC medicament prepared from the linker.

公开(公告)号：US20240358850A1

公开(公告)日：2024-10-31

申请号：US18633864

申请日：2024-04-12

申请人： MaineHealth

发明人： Peter C. Brooks ,  Jennifer M. Caron

IPC分类号： A61K47/68 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K47/6843 ,  A61K39/3955 ,  A61K47/6803 ,  A61K47/68031 ,  A61K47/68033 ,  A61K47/68035 ,  A61K47/6809 ,  A61P35/00

摘要： The present invention provides compositions and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases with antibodies an antigen binding fragments thereof which bind collagen and antibody drug conjugates (ADC). In some embodiments, in the methods provided herein the ADCs target non-cell surface targets associated with tumors.

公开(公告)号：US20240350657A1

公开(公告)日：2024-10-24

申请号：US18622613

申请日：2024-03-29

申请人： PIERRE FABRE MEDICAMENT

发明人： Michel PEREZ ,  Frédéric MARION ,  Jean-François HAEUW ,  Cyrille DREYFUS

IPC分类号： A61K47/68 ,  A61K38/07 ,  A61K38/12 ,  A61K47/54 ,  A61P35/00

CPC分类号： A61K47/6889 ,  A61K38/07 ,  A61K38/12 ,  A61K47/545 ,  A61K47/68031 ,  A61K47/6809 ,  A61K47/6811 ,  A61K47/6849 ,  A61P35/00

摘要： The present invention relates to a linker of the following formula (I) or a salt thereof:




The present invention relates to a linker-drug conjugate of the following formula (II) or a salt thereof:




The present invention relates also to a binding unit-drug conjugate, such as an antibody-drug conjugate, of the following formula (III) or (IV) or a salt thereof:




as well as a pharmaceutical composition comprising such a binding unit-drug conjugate and its use in the treatment of cancer.

公开(公告)号：US20240343826A1

公开(公告)日：2024-10-17

申请号：US18507826

申请日：2023-11-13

申请人： Seagen Inc. ,  The General Hospital Corporation

发明人： David A. Eavarone ,  Julie DeSander ,  Jeffrey Behrens ,  Bo R. Rueda ,  Rosemary Foster ,  Kristen D. Starbuck

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61K47/68 ,  G01N33/574

CPC分类号： C07K16/3069 ,  A61K47/68031 ,  A61K47/6869 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/732

摘要： The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.

公开(公告)号：US20240293570A1

公开(公告)日：2024-09-05

申请号：US18631647

申请日：2024-04-10

申请人： CHENGDU SCIMOUNT PHARMATECH CO., LTD.

发明人： Jinkun HUANG ,  Chenglong WU ,  Chaoyang FENG

IPC分类号： A61K47/68 ,  A61P35/00

CPC分类号： A61K47/6889 ,  A61K47/68031 ,  A61K47/68033 ,  A61K47/68037 ,  A61K47/6849 ,  A61K47/6851 ,  A61P35/00

摘要： A drug link assembly unit has a specific linker structure. Connecting the drug link assembly unit to an antibody forms a targeted linker-drug conjugate. The targeted linker-drug conjugate having the specific linker structure is low in polymer content and naked antibody percentage and proper in DAR value, exhibits excellent plasma stability, storage stability and anti-tumor effect, and has a wide application prospect in preparation of drugs for preventing and/or treating tumors.

公开(公告)号：US20240228645A1

公开(公告)日：2024-07-11

申请号：US18620375

申请日：2024-03-28

申请人： Dragonfly Therapeutics, Inc.

发明人： Benjamin FISCHER ,  Pyae P. HEIN ,  Alexander IVANOV ,  Xinbi LI ,  Matthew SCHNEIDER

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  C07K14/525 ,  C07K14/54 ,  C07K14/55 ,  C07K14/56 ,  C12N5/0783

CPC分类号： C07K16/2878 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/4633 ,  A61K39/4643 ,  A61K47/68031 ,  A61K47/68033 ,  A61K47/68035 ,  A61K47/68037 ,  A61K47/6807 ,  A61K47/6849 ,  C07K14/525 ,  C07K14/5406 ,  C07K14/5428 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/56 ,  C07K16/2809 ,  C12N5/0636 ,  C12N5/0646 ,  C07K2317/31 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

摘要： Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting BAFF-R on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer or autoimmune disease.

公开(公告)号：US20240228612A1

公开(公告)日：2024-07-11

申请号：US18026576

申请日：2021-09-09

申请人： SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

发明人： Cheng WANG ,  Dengnian LIU ,  Fen LI ,  Liang XIAO ,  Tongtong XUE ,  Junyou GE ,  Jingyi WANG ,  Le LIU ,  Qi REN

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K14/725

CPC分类号： C07K16/2803 ,  A61K47/68031 ,  A61K47/68037 ,  A61K47/6849 ,  A61K47/6889 ,  A61P35/00 ,  C07K14/7051 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2319/03

摘要： Provided are an anti-Nectin-4 antibody or antigen-binding fragment thereof, an antibody conjugate comprising the same, and use thereof in the manufacture of a medicament, particularly in the manufacture of a medicament for treating and/or preventing cancer.

公开(公告)号：US20240207431A1

公开(公告)日：2024-06-27

申请号：US18511857

申请日：2023-11-16

申请人： REMEGEN CO., LTD.

发明人： Jianmin FANG ,  Jing JIANG ,  Shenjun LI ,  Xiaohong SU

IPC分类号： A61K47/68 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K47/6851 ,  A61K39/3955 ,  A61K47/68031 ,  A61K47/6889 ,  A61P35/00

摘要： Provided is use of an antibody-drug conjugate targeting Her2 in combination with an immune checkpoint inhibitor such as PD-1 antibody or PD-L1 antibody, in the preparation of a medicine for treating patients with urothelial cancer, especially locally advanced or metastatic urothelial cancer. Compared to treatment with either of the two drugs alone, treatment with both in combination has a marked synergistic effect and significant therapeutic effect. In addition, the combination treatment had good efficacy for patients with low HER2 IHC expression (1+).

公开(公告)号：US20240207424A1

公开(公告)日：2024-06-27

申请号：US18511869

申请日：2023-11-16

申请人： REMEGEN CO., LTD.

发明人： Jianmin FANG ,  Xiaohong SU

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/32

CPC分类号： A61K47/68031 ,  A61K47/6889 ,  A61P35/00 ,  C07K16/32

摘要： Provided is a method for treating a patient with Human Epidermal Growth Factor Receptor 2 (HER2)-low expressing breast cancer.